Copyright
©The Author(s) 2020 Published by Baishideng Publishing Group Inc.
World J Gastroenterol. Aug 14, 2020; 26(30): 4428-4441
Published online Aug 14, 2020. doi: 10.3748/wjg.v26.i30.4428
Published online Aug 14, 2020. doi: 10.3748/wjg.v26.i30.4428
Table 1 Clinical characteristics of study population
| Characteristic | Total (n = 303) | Australia (n = 210) | Oxford (n = 93) | |
| Gender | ||||
| Female, n (%) | 143 (47) | 95 (45) | 48 (52) | |
| Median age VDZ given (range, yr) | 35 (16-84) | 36 (19-78) | 35 (16-84) | |
| Median disease duration (range, yr) | 6 (0.2-48) | 7 (1-48) | 5.4 (0.2-39.2) | |
| Montreal classification, n (%) | ||||
| Age | ||||
| A1 | 34 (11) | 33 (16) | 1 (1) | |
| A2 | 170 (56) | 120 (57) | 50 (54) | |
| A3 | 99 (33) | 57 (27) | 42 (45) | |
| Location | ||||
| E1 | 18 (6) | 15 (7) | 3 (3) | |
| E2 | 114 (38) | 72 (34) | 42 (45) | |
| E3 | 170 (56) | 122 (58) | 48 (52) | |
| Missing | 1 | 1 | 0 | |
| Family History, n (%) | 29 (12) | 22 (15) | 7 (7) | |
| First degree | 19 | 12 | 7 | |
| Second degree | 10 | 10 | 0 | |
| None | 212 | 126 | 86 | |
| Smoking, n | ||||
| Never | 226 | 140 | 86 | |
| Current | 9 | 6 | 3 | |
| Ex smoker | 45 | 41 | 4 | |
| Anti-TNF naïve, n (%) | 182 (60) | 122 (58.1) | 60 (65) | |
| Anti-TNF exposed, n (%) | 121 (40) | 88 (41.9) | 33 (35) | |
| Primary LOR | 45 (15) | 29 (13.8) | 16 (17) | |
| Secondary LOR | 61 (20) | 47 (22.4) | 14 (15) | |
| Side-effects | 15 (5) | 12 (5.7) | 3 (3.2) | |
| Steroids at VDZ initiation, n (%) | 191 (63) | 134 (64) | 57 (61.2) | |
| Prednisone | 162 (53) | 108 (51) | 54 (58) | |
| Budesonide | 29 (10) | 26 (12) | 3 (3) | |
| Immunomodulation at VDZ initiation, n (%) | 175 (58) | 135 (64) | 40 (43) | |
| AZA/6MP | 136 (45) | 108 (51) | 28 (30) | |
| Methotrexate | 19 (6) | 11 (5) | 8 (9) | |
| Tacrolimus | 17 (6) | 16 (8) | 1 (1) | |
| Others (Cyclo&Myco) | 3 (1) | 0 | 3 (3) | |
| Mean Partial Mayo before VDZ initiation | 5 (2-9) | 6 (2-9) | 5 (2-9) | |
Table 2 Response and remission at 3 mo of vedolizumab therapy
| Total | Australia | Oxford | P value | |
| Response, n (%) | 208 (79) | 157 (83) | 51 (70) | 0.01 |
| Remission, n (%) | 148 (56) | 104 (55) | 44 (59) | 0.58 |
| Total | Anti-TNF naive | Anti-TNF exposed | P value | |
| Response, n (%) | 208 (79) | 138 (83) | 70 (72) | 0.03 |
| Remission, n (%) | 148 (56) | 109 (66) | 39 (40) | < 0.001 |
| Anti-TNF exposed | Primary LOR | Secondary LOR | P value | |
| Response, n (%) | 70 (72) | 30 (73) | 40 (71) | 0.85 |
| Remission, n (%) | 39 (40) | 16 (39) | 23 (41) | 0.83 |
Table 3 Remission at 6 mo and 12 mo of vedolizumab therapy
| Total | Australia | Oxford | P value | |
| Remission at 6 mo, n (%) | 147 (62) | 110/173(64) | 37/65 (57) | 0.34 |
| Remission at 12 mo, n (%) | 120/201 (60) | 87/138 (63) | 33/65 (52) | 0.09 |
| Total | Anti-TNF naive | Anti-TNF exposed | ||
| Remission at 6 mo, n (%) | 147/238 (62) | 103/142 (73) | 44/96 (46) | < 0.001 |
| Remission at 12 mo, n (%) | 120/201 (60) | 76/115 (66) | 44/86 (51) | 0.03 |
| Anti-TNF exposed | Primary LOR | Secondary LOR | ||
| Remission at 6 mo, n (%) | 44/96 (46) | 16/42 (38) | 28/54 (52) | 0.18 |
| Remission at 12 mo, n (%) | 44/86 (51) | 17/38 (44) | 27/48 (56) | 0.28 |
Table 4 Complications of vedolizumab therapy
| Complication | Australia (n = 20) | Oxford (n = 5) |
| Respiratory infections | URTI (2) | Pneumonia (1) |
| Sinusitis (4) | Pharyngitis (1) | |
| Nasopharyngitis (1) | ||
| Gastrointestinal Infections | Strongyloidis (1) | Gastroenteritis (1) |
| Clostridium difficile (4) | Buttock abscess (1) | |
| Campylobacter (1) | Oral Thrush (1) | |
| Salmonella (1) | ||
| Serious infections | Haemophagocytic syndrome due to CMV (1) | NA |
| Klebsiella (1) | ||
| Others | Rash (1) | NA |
| Delayed hypersensitivity reaction (1) | ||
| Arthralgia and Headaches (1) |
Table 5 Colectomy at 12 mo of vedolizumab therapy
| Colectomy, n | Australia | Oxford | P value |
| 19/210 | 13/93 | 0.25 | |
| Colectomy, n | Anti-TNF naive | Anti-TNF exposed | P value |
| 9/182 | 23/121 | 0.0005 | |
| Colectomy, n | Primary LOS | Secondary LOS | P value |
| 10/45 | 23/61 | 0.795 |
- Citation: Pulusu SSR, Srinivasan A, Krishnaprasad K, Cheng D, Begun J, Keung C, Van Langenberg D, Thin L, Mogilevski T, De Cruz P, Radford-Smith G, Flanagan E, Bell S, Kashkooli S, Sparrow M, Ghaly S, Bampton P, Sawyer E, Connor S, Rizvi QUA, Andrews JM, Mahy G, Chivers P, Travis S, Lawrance IC. Vedolizumab for ulcerative colitis: Real world outcomes from a multicenter observational cohort of Australia and Oxford. World J Gastroenterol 2020; 26(30): 4428-4441
- URL: https://www.wjgnet.com/1007-9327/full/v26/i30/4428.htm
- DOI: https://dx.doi.org/10.3748/wjg.v26.i30.4428